EGFR and non-small cell lung carcinoma: Although the calculated incidence of EGFR mutations in CNS metastases is lower than previously reported, we are unable to attribute this to technical difficulties since this analysis was performed by two laboratories routinely performing NSCLC molecular diagnostics and involved a large patient cohort.